Patents by Inventor Markus Reschke

Markus Reschke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTICANCER COMBINATION THERAPY
    Publication number: 20230025452
    Abstract: The invention describes anti-cancer therapies comprising using an MDM2 inhibitor in combination with a PD-1 antagonist and a LAG-3 antagonist, each as described herein.
    Type: Application
    Filed: July 15, 2022
    Publication date: January 26, 2023
    Inventors: Dorothea RUDOLPH, Markus RESCHKE
  • ANTI CANCER COMBINATION THERAPY
    Publication number: 20220340651
    Abstract: The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.
    Type: Application
    Filed: November 8, 2021
    Publication date: October 27, 2022
    Inventors: Frank Hilberg, Marco Hans Hofmann, Markus Reschke, Flavio Solca
  • Anti-cancer combination therapy
    Patent number: 11198726
    Abstract: The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: December 14, 2021
    Assignee: Boerhinger Ingelheim International GmbH
    Inventors: Frank Hilberg, Marco Hans Hofmann, Markus Reschke, Flavio Solca
  • ANTI IGF, ANTI PD-1, ANTI-CANCER COMBINATION THERAPY
    Publication number: 20200239559
    Abstract: The disclosure relates to the combined use of certain anti-IGF antibody molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such anti-IGF antibody molecules and antagonists.
    Type: Application
    Filed: September 28, 2018
    Publication date: July 30, 2020
    Inventors: Ulrike WEYER-CZERNILOFSKY, Markus RESCHKE
  • ANTICANCER COMBINATION THERAPY
    Publication number: 20200101079
    Abstract: The invention describes anti-cancer therapies comprising using an MDM2 inhibitor in combination with a PD-1 antagonist and a LAG-3 antagonist, each as described herein.
    Type: Application
    Filed: April 4, 2018
    Publication date: April 2, 2020
    Inventors: Dorothea RUDOLPH, Markus RESCHKE
  • ANTICANCER COMBINATION THERAPY
    Publication number: 20200046684
    Abstract: The invention describes anti-cancer therapies comprising using a SMAC mimetic in combination with a PD-1 antagonist, each as described herein.
    Type: Application
    Filed: March 29, 2018
    Publication date: February 13, 2020
    Inventors: Maria IMPAGNATIELLO, Markus RESCHKE
  • ANTI-CANCER COMBINATION THERAPY
    Publication number: 20180346559
    Abstract: The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 6, 2018
    Inventors: Frank Hilberg, Marco Hans Hofmann, Markus Reschke, Flavio Solca
  • CHARACTERIZATION AND ANALYSIS OF THE COMPOSITION AND DYNAMICS OF THE MAMMALIAN RIBOPROTEOME
    Publication number: 20150079590
    Abstract: The present invention relates to methods for identifying compounds that modulate the translation machinery and methods of diagnosing cancer related to deregulation of the translation machinery. In particular, the methods and diagnostic tests include determining an association between one or more targets and one or more components of the riboproteome and treating a subject with cancer by administering a compound that modulates the association between one or more targets and one or more components of the riboproteome.
    Type: Application
    Filed: September 17, 2014
    Publication date: March 19, 2015
    Inventors: Pier Paolo PANDOLFI, Markus RESCHKE, John CLOHESSY
  • HER3 AS A DETERMINANT FOR THE PROGNOSIS OF MELANOMA
    Publication number: 20110033482
    Abstract: Disclosed are inhibitors of HER3 for the treatment of melanoma, in particular melanoma metastases and/or refractory melanoma, pharmaceutical compositions comprising such an inhibitor and a method for the diagnosis or prognosis of melanoma.
    Type: Application
    Filed: June 26, 2009
    Publication date: February 10, 2011
    Inventors: Axel Ullrich, Pjotr Knyazev, Markus Reschke